AstraZeneca and Eli Lilly deepening their collaboration in cancer immunotherapy by testing new drug combinations for treating solid tumours.
Eli Lilly and Company, a global healthcare leader, has launched
Humalog 200 units/ml KwikPen (insulin lispro 200 units/m; U-200), the first and only concentrated mealtime insulin analog in the US.
A new medication to be launched by the end of this year by US Pharma major Eli Lilly, for diabetic patients in India. A regulatory approval for the upcoming product has already been received by the company. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or early 2017 which has been filed for approvals.
US Food and Drug Administration (FDA) has approved Eli Lilly and Company Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro 100 units/mL) Humalog U-200 KwikPen is used to improve glycemic control in people with type 1 and type 2 diabetes.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
